Intercept Pharmaceuticals (ICPT) Key Ratios
$19.00
$0.00 (0.00%)As on 14-Nov-2023 09:30EDT
Market cap
$795 Mln
Revenue (TTM)
$318 Mln
P/E Ratio
--
P/B Ratio
44.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 6.06 | 14.44 | -3.83 | 1.82 | 14.11 |
| EBIT | 170.92 | 149.77 | 4.63 | 21.62 | 12.83 |
| Net Profit | 52.41 | -101.61 | -159.53 | 22.23 | 12.77 |
| EPS | 52.47 | -101.32 | -155.73 | 22.89 | 13.53 |
| Book Value | -- | -- | -- | 12.58 | 28.06 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -36.16 | -78.01 | -16.56 | -23.88 | -15.34 |
| Net Margin
| -27.58 | -79.68 | -17.85 | 57.46 | -37.95 |
| Return on equity
| 130.55 | -491.24 | -84.31 | -253.45 | 82.68 |
| Return on Capital
| -24.44 | -44.02 | -- | 29.20 | -37.57 |
| Return on Assets
| -17.81 | -35.51 | -9.27 | 21.31 | -26.19 |
| Debt to Equity (x)
| -- | -- | 3.12 | 3.57 | -2.97 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
29.20
|
-37.57
|
-64.93
|
-73.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-84.31
Lower than Peers by 43.91
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-84.31
|
-253.45
|
82.68
|
562.43
|
-1,106.45
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-9.27
Higher than Peers by 21.71
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-9.27
|
21.31
|
-26.19
|
-48.56
|
-61.87
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-16.56
Higher than Peers by 67.06
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-16.56
|
-23.88
|
-15.34
|
-69.27
|
-123.98
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-17.85
Higher than Peers by 74.82
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-17.85
|
57.46
|
-37.95
|
-102.25
|
-149.89
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-3.83
Lower than Peers by 57.78
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-3.83
|
-0.21
|
0.16
|
0.24
|
0.40
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
4.63
Higher than Peers by 5.43
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
4.63
|
-22.34
|
74.26
|
30.67
|
-10.28
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-159.53
Lower than Peers by 152.23
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-159.53
|
179.42
|
55.27
|
17.09
|
-26.46
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-155.73
Lower than Peers by 170.38
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-155.73
|
1.57
|
0.50
|
0.18
|
-0.14
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-45.25
Lower than Peers by 35.07
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-45.25
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
3.12
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
3.12
|
3.57
|
-2.97
|
-3.45
|
10.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
1.18
|
-0.02
|
-0.04
|
0.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.22
Lower than Peers by 1.59
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
4.22
|
2.35
|
3.01
|
2.66
|
4.45
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
4.19
Lower than Peers by 1.50
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
4.19
|
2.32
|
2.96
|
3.05
|
4.40
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-4.81
Lower than Peers by 2.73
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-4.81
|
-3.19
|
-1.02
|
-4.51
|
-7.59
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
10.22
Lower than Peers by 8.92
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
10.22
|
9.40
|
13.10
|
13.29
|
15.10
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.50
Higher than Peers by 0.44
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
0.50
|
0.53
|
0.66
|
0.47
|
0.40
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
47.61
|
44.80
|
46.49
|
46.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
2,798.95
|
-3,531.85
|
-2,062.65
|
675.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
6,006.95
|
2,517.04
|
1,495.07
|
1,332.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
-3,160.39
|
-6,004.09
|
-3,511.24
|
-611.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
4.45
|
-3.32
|
-2.51
|
-10.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
44.19
Higher than Peers by 39.01
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
44.19
|
5.51
|
-2.62
|
-4.89
|
78.79
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-3.59
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
-3.59
|
-5.84
|
-11.36
|
-4.34
|
-13.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
795
Higher than Peers by 649
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
|
795
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|